Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Open Forum Infectious Diseases Année : 2019

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients

Résumé

Ibrutinib is an oral first-in-class Bruton’s tyrosine kinase inhibitor approved for the therapy of various B-cell lymphoid malignancies. Among ibrutinib-related infections, viral hepatitis are poorly described. We report our single-center experience with 4 cases of chronic hepatitis E virus infection and their management with ribavirin.

Dates et versions

hal-03355772 , version 1 (27-09-2021)

Identifiants

Citer

Caroline Protin, Florence Abravanel, Laurent Alric, Suzanne Tavitian, Lucie Obéric, et al.. Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients. Open Forum Infectious Diseases, 2019, 6 (9), pp.1-3. ⟨10.1093/ofid/ofz345⟩. ⟨hal-03355772⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More